行情

CNTX

CNTX

Centrexion Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

0.0000
0.0000
0.00%
停牌
开盘
--
昨收
--
最高
--
最低
--
成交量
--
成交额
--
52周最高
--
52周最低
--
市值
0
市盈率(TTM)
0.0000
分时
5日
1月
3月
1年
5年

CNTX 新闻

  • 泰国和俄罗斯计划2020年使两国贸易额达到100亿美元
  • 新浪财经综合.7小时前
  • 亏损不断扩大 阿斯顿-马丁将引入新投资者
  • 新浪财经-自媒体综合.7小时前
  • 马斯克:太阳能、能源存储业务将超越电动车业务
  • 新浪美股.9小时前
  • iPhone降到1999就能统治市场?其他手机笑出声
  • 新浪财经综合.10小时前

更多

所属板块

制药
-0.74%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

CNTX 简况

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.
展开

Webull提供Centrexion Therapeutics Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。